CN100360117C - 具有提高的溶出度的药物组合物 - Google Patents

具有提高的溶出度的药物组合物 Download PDF

Info

Publication number
CN100360117C
CN100360117C CNB038171481A CN03817148A CN100360117C CN 100360117 C CN100360117 C CN 100360117C CN B038171481 A CNB038171481 A CN B038171481A CN 03817148 A CN03817148 A CN 03817148A CN 100360117 C CN100360117 C CN 100360117C
Authority
CN
China
Prior art keywords
celecoxib
salt
precipitation
registration number
cas registration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038171481A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668283A (zh
Inventor
J·雷门纳
M·彼得森
O·阿尔马森
H·古日曼
陈红敏
M·塔瓦
M·奥利弗拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transform Pharmaceuticals Inc
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Publication of CN1668283A publication Critical patent/CN1668283A/zh
Application granted granted Critical
Publication of CN100360117C publication Critical patent/CN100360117C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNB038171481A 2002-06-21 2003-06-20 具有提高的溶出度的药物组合物 Expired - Fee Related CN100360117C (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US39088102P 2002-06-21 2002-06-21
US60/390,881 2002-06-21
US42627502P 2002-11-14 2002-11-14
US60/426,275 2002-11-14
US42708602P 2002-11-15 2002-11-15
US60/427,086 2002-11-15
US42951502P 2002-11-26 2002-11-26
US60/429,515 2002-11-26
US43751602P 2002-12-30 2002-12-30
US60/437,516 2002-12-30
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
PCT/US2003/019574 WO2004000284A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution

Publications (2)

Publication Number Publication Date
CN1668283A CN1668283A (zh) 2005-09-14
CN100360117C true CN100360117C (zh) 2008-01-09

Family

ID=30004092

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038171481A Expired - Fee Related CN100360117C (zh) 2002-06-21 2003-06-20 具有提高的溶出度的药物组合物

Country Status (9)

Country Link
US (2) US20050025791A1 (https=)
EP (1) EP1515703A1 (https=)
JP (1) JP2006500377A (https=)
CN (1) CN100360117C (https=)
AU (2) AU2003243699B2 (https=)
CA (1) CA2489984A1 (https=)
IL (2) IL165383A0 (https=)
MX (1) MXPA05000232A (https=)
WO (1) WO2004000284A1 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
ES2369256T3 (es) * 2000-06-26 2011-11-28 Helen Of Troy Limited Sistema de lámpara recargable.
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
PL1916994T3 (pl) * 2004-06-29 2014-05-30 Takeda Pharma As Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
DE602005010604D1 (de) * 2004-11-17 2008-12-04 Ares Trading Sa Benzothiazolformulierungen und ihre verwendung
US20080319068A1 (en) * 2005-04-27 2008-12-25 Transform Pharmaceuticals, Inc. Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same
EP1902713A4 (en) * 2005-07-08 2009-05-13 Daiichi Sankyo Co Ltd A PHIAZEUTIC COMPOSITION CONTAINING A THIAZOLIDINDEIDE COMPOUND
US8247609B2 (en) * 2005-10-25 2012-08-21 Pharamleads Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors
DE102005056592A1 (de) * 2005-11-25 2007-05-31 Basf Ag Herstellung und Verwendung von hochfunktionellen, hoch-oder hyperverzweigten Polylysinen
KR101304982B1 (ko) * 2006-05-08 2013-09-06 (주)아모레퍼시픽 경피흡수용 조성물 및 이로부터 형성된 고분자 매트릭스함유 경피흡수제제
WO2008085674A1 (en) * 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
JP4521788B2 (ja) * 2007-06-25 2010-08-11 Ｓａｉ株式会社 ガス充填式キャピラリー及び試料充填方法
RU2453332C2 (ru) * 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
WO2010134085A1 (en) * 2009-05-20 2010-11-25 Institute Of Life Sciences Pharmaceutical co-crystals of quercetin
EP2325172A1 (en) * 2009-11-02 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of celecoxib and L-proline
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
EP2598488A1 (en) * 2010-07-30 2013-06-05 McNeil-PPC, Inc. Hydrated sodium salt form of celecoxib
US20130059448A1 (en) * 2011-09-07 2013-03-07 Lam Research Corporation Pulsed Plasma Chamber in Dual Chamber Configuration
US9793126B2 (en) 2010-08-04 2017-10-17 Lam Research Corporation Ion to neutral control for wafer processing with dual plasma source reactor
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone
BR112013006651A2 (pt) * 2010-09-23 2017-07-18 Nuformix Ltd composição e cocristal de aprepitante l-prolina
MX357583B (es) * 2011-06-07 2018-07-16 Firmenich & Cie Capsulas de nucleo-corteza.
AR087716A1 (es) 2011-08-31 2014-04-09 Valent Biosciences Corp Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas
US9039911B2 (en) 2012-08-27 2015-05-26 Lam Research Corporation Plasma-enhanced etching in an augmented plasma processing system
EP2780016A4 (en) 2011-11-07 2015-08-05 Diakron Pharmaceuticals Inc EXTENDED RELEASE FORMULATION OF DIRECT THROMBIN INHIBITOR
CN108640910A (zh) 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
JP5787734B2 (ja) * 2011-12-07 2015-09-30 株式会社ソミック石川 アームの製造方法
WO2014041489A2 (en) * 2012-09-11 2014-03-20 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
US9245761B2 (en) 2013-04-05 2016-01-26 Lam Research Corporation Internal plasma grid for semiconductor fabrication
US9230819B2 (en) 2013-04-05 2016-01-05 Lam Research Corporation Internal plasma grid applications for semiconductor fabrication in context of ion-ion plasma processing
US9017526B2 (en) 2013-07-08 2015-04-28 Lam Research Corporation Ion beam etching system
US9147581B2 (en) 2013-07-11 2015-09-29 Lam Research Corporation Dual chamber plasma etcher with ion accelerator
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
RU2708254C2 (ru) 2015-05-28 2019-12-05 Др. Редди'С Лабораториз Лтд. Пероральная композиция целекоксиба для лечения боли
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
TW201818933A (zh) * 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
CN113679669B (zh) * 2017-08-15 2022-08-23 江苏恒瑞医药股份有限公司 一种包含艾瑞昔布的药物组合物
US12521201B2 (en) 2017-12-07 2026-01-13 Augmedics Ltd. Spinous process clamp
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM
CN109336816A (zh) * 2018-09-29 2019-02-15 中国药科大学 一种塞来昔布吲哚美辛的共无定形物
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
CN110204438B (zh) * 2019-06-10 2021-10-22 浙江科技学院 一种丁二酸、戊二酸的分离方法
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
EP4125404A1 (en) * 2020-04-03 2023-02-08 Aizant Drug Research Solutions Private Limited Coated chewing gum compositions
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US12502163B2 (en) 2020-09-09 2025-12-23 Augmedics Ltd. Universal tool adapter for image-guided surgery
CN114681470A (zh) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
US12475662B2 (en) 2021-08-18 2025-11-18 Augmedics Ltd. Stereoscopic display and digital loupe for augmented-reality near-eye display
AU2022338032A1 (en) 2021-08-31 2024-03-07 Cerespir Incorporated Co-crystals
CN119325384A (zh) * 2022-02-11 2025-01-17 布里克斯顿生物科学有限公司 用于具有透明质酸的冷浆料的组合物和方法
WO2023203521A1 (en) 2022-04-21 2023-10-26 Augmedics Ltd. Systems and methods for medical image visualization
JP2025531829A (ja) 2022-09-13 2025-09-25 オーグメディックス リミテッド 画像誘導医療介入のための拡張現実アイウェア
CN115684514B (zh) * 2022-11-24 2024-04-26 则正(济南)生物科技有限公司 评价仿制药和原研药生物利用度的方法及其应用
WO2024150261A1 (en) * 2023-01-10 2024-07-18 Zarqa University An oral pharmaceutical formulation and a method of preparation thereof
CN118767141A (zh) * 2023-04-04 2024-10-15 上海汇伦医药股份有限公司 西维来司他用于镇痛的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1141630A (zh) * 1993-11-30 1997-01-29 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2711411A (en) 1955-06-21 B-bromotheophylijne salt of z-amino-z-
US2665277A (en) 1950-10-17 1954-01-05 Mallinckrodt Chemical Works Monobasic morphine phosphate hemihydrate and process of preparing same
US3028420A (en) 1959-06-26 1962-04-03 British Drug Houses Ltd Compound of betaine and chloral and method for preparing same
GB1297261A (https=) 1969-01-13 1972-11-22
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3970651A (en) 1974-01-07 1976-07-20 Bristol-Myers Company Crystalline cephalosporin derivative
JPS5842168B2 (ja) * 1974-12-20 1983-09-17 トウコウヤクヒンコウギヨウ カブシキガイシヤ 局所用剤の製造方法
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5495589A (en) * 1977-12-30 1979-07-28 Sumitomo Chem Co Ltd Production of cephalosporin derivative
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4198507A (en) 1978-11-13 1980-04-15 Hoffmann-La Roche Inc. Theophylline magnesium salicylate
US4368197A (en) 1979-02-21 1983-01-11 Research Corporation Zinc aminophylline and its use in the treatment of bronchospasms
US5366738A (en) 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
LU84515A1 (fr) * 1982-12-09 1984-10-22 Oreal Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8500862D0 (en) 1985-01-14 1985-02-20 Tate & Lyle Plc Composition
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
NZ223799A (en) 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
JP2581707B2 (ja) 1987-10-02 1997-02-12 科研製薬株式会社 抗真菌剤組成物
US5006513A (en) 1987-11-09 1991-04-09 Miles Inc. Antimycotic compositions of nikkomycin compounds and azole antimycotica
US5023092A (en) 1988-06-16 1991-06-11 Ici Americas Inc. Mannitol having gamma sorbitol polymorph
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US4925674A (en) 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US4994604A (en) 1990-01-10 1991-02-19 Merck & Co., Inc. Formation and resolution of ibuprofen lysinate
IT1242642B (it) 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5177262A (en) 1991-07-19 1993-01-05 Polaroid Corporation Process and composition for use in photographic materials containing hydroquinones
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
RU2127733C1 (ru) 1992-03-18 1999-03-20 Жансен Фармасетика Н.В. Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US5380867A (en) 1992-12-02 1995-01-10 Hoechst Celanese Corporation Selective precipitation of α-aryl carboxylic acid salts
US5332834A (en) 1992-12-02 1994-07-26 Hoechst Celanese Corporation Racemization of an enantomerically enriched α-aryl carboxylic acid
US5412997A (en) * 1992-12-11 1995-05-09 Industrial Technology Research Institute Nondestructive testing apparatus and method
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5414997A (en) 1993-01-11 1995-05-16 Tailer; Peter L. Thermal lag machine
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CA2154777A1 (en) 1993-01-27 1994-08-04 Nancy M. Gray Method and composition employing (2r,4s) itraconazole
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5412094A (en) 1993-06-28 1995-05-02 Eli Lilly And Company Bicyclic beta-lactam/paraben complexes
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5661151A (en) 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
IL112081A (en) 1993-12-21 2001-08-26 Schering Plough Corp Tetrahydrofuran derivatives, their preparation and antifungal pharmaceutical compositions containing them
GB9404248D0 (en) * 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FI944182L (fi) 1994-09-09 1996-03-10 Xyrofin Oy Yhtenäiskiteitä sisältävä koostumus, menetelmä sen valmistamiseksi ja sen käyttö
IN182620B (https=) 1994-10-24 1999-05-15 Vikas Bajaj
BR9607035A (pt) 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5523090A (en) 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5631250A (en) 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
US5614342A (en) 1995-05-02 1997-03-25 Eastman Kodak Company Methods for preparing cocrystals of titanyl fluorophthalocyanines and unsubstituted titanyl phthalocyanine, electrophotographic elements, and titanyl phthalocyanine compositions
US6001996A (en) 1995-05-11 1999-12-14 Eli Lilly And Company Complexes of cephalosporins and carbacephalosporins with parabens
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
US5952187A (en) 1995-12-01 1999-09-14 Oxis International, Inc. Topiramate immunoassay
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
ATE233743T1 (de) 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
RU2214241C2 (ru) 1996-06-28 2003-10-20 Орто-Макнейл Фармасьютикал, Инк. Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
US5994365A (en) 1997-02-25 1999-11-30 Diazans Limited Substituted diazaanthracene compounds having pharmaceutical utility
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
US5935933A (en) 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU1623099A (en) 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
AU1937099A (en) 1997-12-31 1999-07-19 Alza Corporation Osmotic drug delivery monitoring system and method
DE69904292T2 (de) 1998-01-21 2003-08-14 Reflexite Corp., Avon Langzeitbeständige fluoreszendierende polyvinylchloridfolie
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IL142807A0 (en) 1998-11-02 2002-03-10 Alza Corp Controlled delivery of active agents
ES2234324T3 (es) 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
ATE279921T1 (de) 1999-01-19 2004-11-15 Ortho Mcneil Pharm Inc Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
WO2000061136A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering blood pressure
AU768393B2 (en) 1999-05-28 2003-12-11 Jeffrey Berlant Compounds and methods for the treatment of post traumatic stress disorder
US6413965B1 (en) 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
PL213323B1 (pl) 1999-08-20 2013-02-28 Ortho Mcneil Pharm Inc Kompozycja farmaceutyczna i jej zastosowanie
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
EP1212051A4 (en) 1999-08-27 2004-03-31 Merck & Co Inc METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN
HUP0201450A3 (en) 1999-12-08 2003-02-28 Pharmacia Corp Chicago Solid-state form of celecoxib having enhanced bioavailability, pharmaceutical compositions containing it and their preparation
ES2236011T3 (es) * 1999-12-08 2005-07-16 Pharmacia Corporation Formas cristalinas polimorficas de celecoxib.
PL351069A1 (en) 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
KR100793668B1 (ko) * 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
ES2258988T3 (es) 1999-12-22 2006-09-16 Pharmacia Corporation Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2.
CN1434713A (zh) 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
EP1120109A3 (en) 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
CA2406226A1 (en) 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
GB0015239D0 (en) 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
TR200001872A3 (tr) 2000-06-26 2002-01-21 Fako Ilaclari A.S 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem.
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
WO2005077894A1 (en) 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
ES2277937T3 (es) 2000-07-27 2007-08-01 Teva Pharmaceutical Industries Ltd. Modafinilo puro y cristalino y su procedimiento de preparacion.
DK1309315T3 (da) 2000-08-18 2006-10-09 Pharmacia Corp Hurtigt disintegrerende oral valdecoxib-formulering
US20020119193A1 (en) 2000-08-18 2002-08-29 Le Trang T. Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
IN191090B (https=) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
UA78211C2 (en) 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US6688443B2 (en) 2001-11-07 2004-02-10 L & P Property Management Company Apparatus and method for double clutch actuator
US20030072802A1 (en) 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
AU2002334987A1 (en) 2001-10-15 2003-04-28 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
CA2363376A1 (en) 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20090088443A1 (en) 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
WO2004089313A2 (en) 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20040171062A1 (en) 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
EP1364649A1 (en) 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
EP1511490A4 (en) 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US20070059356A1 (en) 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
AU2003267231A1 (en) * 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US7033716B2 (en) 2002-12-02 2006-04-25 Eastman Kodak Company Two-stage milling process for preparing cocrystals of titanyl fluorophthalocyanine and titanyl phthalocyanine, and electrophotographic element containing same
US7033715B2 (en) 2002-12-02 2006-04-25 Eastman Kodak Company Uniform cocrystals of titanyl fluorophthalocyanine and titanyl phthalocyanine formed in trichloroethane, and charge generating layer containing same
US6949139B2 (en) 2002-12-02 2005-09-27 Eastman Kodak Company Process for forming cocrystals containing chlorine-free titanyl phthalocyanines and low concentration of titanyl fluorophthalocyanine using organic milling aid
PL377351A1 (pl) 2002-12-13 2006-01-23 Cilag Ag Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
EP1596869B1 (en) 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
ATE550022T1 (de) 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
NZ545133A (en) 2003-09-04 2009-12-24 Cephalon Inc Modafinil compositions
US7566805B2 (en) 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
US7892354B2 (en) 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
JP4994039B2 (ja) 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
US9682043B2 (en) 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
EP2292585B1 (en) 2004-03-12 2016-04-27 Aptuit (West Lafayette), LLC Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound
EP1732529A4 (en) 2004-03-25 2009-02-25 Univ Michigan GOSSYPOL KOKRISTALLE AND ITS USE
EP1742941A1 (en) 2004-04-22 2007-01-17 Transform Pharmaceuticals, Inc. Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods
US20050252649A1 (en) 2004-05-11 2005-11-17 Ming-Chi Chiu Leadless lower temperature co-crystal phase transition metal heat conductive device
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
WO2006024930A1 (en) 2004-09-01 2006-03-09 Pharmacia & Upjohn Company Llc Novel co-crystals between polyethylene glycols and 5-phenylpyrazolyl-1-benzenesulfonamides
US20080319068A1 (en) 2005-04-27 2008-12-25 Transform Pharmaceuticals, Inc. Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same
JP4633588B2 (ja) 2005-09-20 2011-02-16 Ｋｄｄｉ株式会社 気象データ配信装置および局域気象データ配信システムならびに同システムにおける気象データ推定方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1141630A (zh) * 1993-11-30 1997-01-29 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Also Published As

Publication number Publication date
AU2009201465A1 (en) 2009-05-07
WO2004000284A1 (en) 2003-12-31
CN1668283A (zh) 2005-09-14
AU2003243699A1 (en) 2004-01-06
JP2006500377A (ja) 2006-01-05
MXPA05000232A (es) 2005-06-17
HK1080717A1 (zh) 2006-05-04
CA2489984A1 (en) 2003-12-31
AU2009201465B2 (en) 2011-06-30
IL165383A (en) 2011-10-31
EP1515703A1 (en) 2005-03-23
IL165383A0 (en) 2006-01-15
US20050025791A1 (en) 2005-02-03
AU2003243699B2 (en) 2009-01-15
US20060134198A1 (en) 2006-06-22
US8362062B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
CN100360117C (zh) 具有提高的溶出度的药物组合物
AU2002254609B2 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (COX-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
CN1376146B (zh) 提高了生物利用率的雪列柯西的固态形式
ES2236007T3 (es) Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
CZ20013210A3 (cs) Pevná forma celecoxibu mající zvýąenou biologickou dostupnost
EA020624B1 (ru) Кристаллическая полиморфная форма n-(-)-(3,4-дифтор-2-(2-фтор-4-йодфениламино)-6-метоксифенил)-l-(2,3-дигидроксипропил)циклопропан-1-сульфонамида и ее применение в качестве ингибитора mek
BG105873A (bg) Валдекоксибни състави
AU2023274142B2 (en) Crystal
CZ20012875A3 (cs) Polymorfní krystalické formy celecoxibu
US20060052432A1 (en) Pharmaceutical compositions with improved dissolution
CN1615135A (zh) 磺酰胺前药如帕瑞考昔的口服剂型
WO2004061433A1 (en) Pharmaceutical compositions with improved dissolution
JP5021934B2 (ja) 改善された溶解性を有する医薬組成物
EP2339328A2 (en) Pharmaceutical co-crystal compositions of celecoxib
HK1080717B (en) Pharmaceutical compositions with improved dissolution
JP2008528568A (ja) Ｉｖ型結晶のセレコキシブ
KR20050016596A (ko) 용해성이 개선된 약학 조성물
ZA200307576B (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (Cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080717

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1080717

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080109

Termination date: 20200620

CF01 Termination of patent right due to non-payment of annual fee